1768: Prognostic Significance of Plasma Placental Growth Factor Levels in Renal Cell Cancer: An Association with Clinical Characteristics and Vascular Endothelial Growth Factor Levels

2004 ◽  
Vol 171 (4S) ◽  
pp. 467-467 ◽  
Author(s):  
Kazuhisa Matsumoto ◽  
Kazuhiro Suzuki ◽  
Hidekazu Koike ◽  
Keigo Okamura ◽  
Kiyotaka Tsuchiya ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Clinical Characteristics ◽  
Cell Cancer ◽  
Prognostic Significance ◽  
Placental Growth Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Novelties of treatment in advanced renal-cell cancer

2011 ◽  
Vol 152 (17) ◽  
pp. 655-662 ◽  
Author(s):  
Anikó Maráz
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Current Evidence ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Advanced Renal Cell Cancer

Therapeutic options in advanced renal-cell cancer have expanded through better understanding of molecular patho­logy and development of novel targeted therapeutics. Vascular endothelial growth factor, the key ligand of angioge­nesis, has a major role in the progression of vascularized kidney tumors and this is the target molecule of modern medications. The three types of the mechanism of action of current therapies are: monoclonal antibodies blocking directly vascular endothelial growth factor ligand (bevacizumab), tyrosine-kinase inhibitors blocking vascular endothelial growth factor receptors (sorafenib, sunitinib, pazopanib) and inhibitors of the intracellular mTOR-kinase (temsirolimus, everolimus). Based on randomized studies, sunitinib, pazopanib or interferon-α-bevacizumab combination should be the first-line therapy in patients with good/moderate prognosis, while temsirolimus is recommended in those with poor prognosis. Following an ineffective cytokine therapy sorafenib or pazopanib are the se­cond-line treatment. In case of tyrosine-kinase inhibitor inefficacy, current evidence favors everolimus. Patient outcome can further be improved by the involvement of more modern and effective target products. Orv. Hetil., 2011, 152, 655–662.

scholarly journals Expression of Hypoxia-Inducible Factor (HIF)-1αand Vascular Endothelial Growth Factor (VEGF)-D As Outcome Predictors in Resected Esophageal Squamous Cell Carcinoma

2008 ◽  
Vol 25 (3) ◽  
pp. 141-148 ◽  
Author(s):  
Ching Tzao ◽  
Shih-Chun Lee ◽  
Ho-Jui Tung ◽  
Han-Shui Hsu ◽  
Wen-Hu Hsu ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Squamous Cell ◽  
Cell Cancer ◽  
Hypoxia Inducible Factor ◽  
Prognostic Significance ◽  
Tumor Stage ◽  
Angiogenic Factors ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Hypoxia-inducible factor (HIF)-1αand vascular endothelial growth factor (VEGF) are important angiogenic factors in human cancers. Relative to VEGF-C, prognostic significance of VEGF-D expression and its association with HIF-1αexpression remain elusive in esophageal squamous cell cancer (ESCC). We studied expression of HIF-1αand VEGF-D using immunohistochemistry in 85 resected ESCC specimens and correlated results with patients' clinicopathologic parameters and survival. Association between expression of HIF-1αand VEGF-D was investigated using a concordance analysis. High expression of HIF-1αand VEGF-D was observed in 52 (61.2%) and 56 (65.9%) patients, respectively. HIF-1αexpression correlated well with tumor stage (P= 0.041), whereas VEGF-D expression correlated with tumor stage (P= 0.027) and N status (P= 0.019). Groups of high HIF-1αand VEGF-D showed worse survivals than those of low expression (P= 0.002 and 0.001, respectively). Multivariate analysis supported expression of HIF-1αand VEGF-D as significant survival predictors (P= 0.044 and 0.035, respectively). A concordance rate of 69.5% was observed between expression of HIF-1αand VEGF-D. In conclusion, protein expression of HIF-1αand VEGF-D are independent prognostic predictors. An association between expression of HIF-1αand VEGF-D suggests that these two angiogenic factors are essential in progression of ESCC.

Sign in / Sign up

Export Citation Format

Share Document